DZ2953A1 - Méthodes de réduction des niveaux de glucose et triglycérides en sérum et pour suppression de l'anti-genèse utilisant les acides la indoleakanoique. - Google Patents

Méthodes de réduction des niveaux de glucose et triglycérides en sérum et pour suppression de l'anti-genèse utilisant les acides la indoleakanoique.

Info

Publication number
DZ2953A1
DZ2953A1 DZ990253A DZ990253A DZ2953A1 DZ 2953 A1 DZ2953 A1 DZ 2953A1 DZ 990253 A DZ990253 A DZ 990253A DZ 990253 A DZ990253 A DZ 990253A DZ 2953 A1 DZ2953 A1 DZ 2953A1
Authority
DZ
Algeria
Prior art keywords
indoleakanoic
genesis
triglycerides
suppression
serum
Prior art date
Application number
DZ990253A
Other languages
English (en)
Inventor
Janet Sredy
Jorge Jacot
Original Assignee
Inst For Pharm Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst For Pharm Discovery Inc filed Critical Inst For Pharm Discovery Inc
Application granted granted Critical
Publication of DZ2953A1 publication Critical patent/DZ2953A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DZ990253A 1998-12-01 1999-12-01 Méthodes de réduction des niveaux de glucose et triglycérides en sérum et pour suppression de l'anti-genèse utilisant les acides la indoleakanoique. DZ2953A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11039598P 1998-12-01 1998-12-01

Publications (1)

Publication Number Publication Date
DZ2953A1 true DZ2953A1 (fr) 2004-03-15

Family

ID=22332786

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ990253A DZ2953A1 (fr) 1998-12-01 1999-12-01 Méthodes de réduction des niveaux de glucose et triglycérides en sérum et pour suppression de l'anti-genèse utilisant les acides la indoleakanoique.

Country Status (30)

Country Link
US (5) US6555568B1 (fr)
EP (1) EP1135124B1 (fr)
JP (1) JP2002531398A (fr)
KR (1) KR20010086075A (fr)
CN (1) CN1368883A (fr)
AP (1) AP2001002146A0 (fr)
AT (1) ATE265210T1 (fr)
AU (1) AU770925B2 (fr)
BG (1) BG105531A (fr)
BR (1) BR9915882A (fr)
CA (1) CA2385845A1 (fr)
CZ (1) CZ20011864A3 (fr)
DE (1) DE69916881T2 (fr)
DZ (1) DZ2953A1 (fr)
EE (1) EE200100296A (fr)
HK (1) HK1046372A1 (fr)
HU (1) HUP0104953A3 (fr)
ID (1) ID30037A (fr)
IL (1) IL143247A0 (fr)
MX (1) MXPA02003118A (fr)
NO (1) NO20012690L (fr)
OA (1) OA12035A (fr)
PL (1) PL349016A1 (fr)
SK (1) SK7352001A3 (fr)
TN (1) TNSN99224A1 (fr)
TR (1) TR200101539T2 (fr)
TW (1) TW584560B (fr)
WO (1) WO2000032180A2 (fr)
YU (1) YU40101A (fr)
ZA (1) ZA200104126B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2224632T3 (es) * 1998-03-31 2005-03-01 The Institutes For Pharmaceutical Discovery, Inc. Acidos indolalcanoicos sustituidos.
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
WO2001064205A2 (fr) * 2000-03-02 2001-09-07 The Institutes For Pharmaceutical Discovery, Llc Compositions contenant un acide indol-alkanoique substitue et inhibiteur d'enzyme de conversion de l'angiotensine
US20020012630A1 (en) * 2000-05-09 2002-01-31 James Nolan Methods for testing compounds useful in treating diabetic complications
EP1397130B1 (fr) 2001-06-20 2007-07-25 Wyeth Derives d'acide indole substitue utilises en tant qu'inhibiteurs de l'inhibiteur-1 (pai-1) de l'activateur plasminogene
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
DE60306548T2 (de) 2002-12-10 2007-06-21 Wyeth Substituierte 3-carbonyl-1-yl-essigsäure-derivate als plasminogen aktivator inhibitor(pai-1) inhibitoren
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
ES2268480T3 (es) 2002-12-10 2007-03-16 Wyeth Derivados del acido 3-alquilo- y 3-arilalquilo-1h-indol-1-il-acetico sustituidos como inhibidores del inhibidor del activador del plasminogeno-1 (pai-1).
US7056943B2 (en) 2002-12-10 2006-06-06 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
CN1723198A (zh) 2002-12-10 2006-01-18 惠氏公司 用作纤溶酶原激活物抑制剂－1(pai－1)的抑制剂的芳基、芳氧基和烷氧基取代的1h－吲哚－3－基乙醛酸衍生物
US7592361B2 (en) 2003-04-28 2009-09-22 Bayer Pharmaceuticals Corporation Indole acetic acid derivatives and their use as pharmaceutical agents
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
BRPI0514544A (pt) 2004-08-23 2008-06-17 Wyeth Corp ácidos de oxazol-naftila como moduladores de inibidor tipo-1 de ativador de plasminogênio (pai-1)
CA2589896A1 (fr) * 2004-11-30 2006-06-08 Plexxikon, Inc. Derives de l'indole servant de composes actifs du ppar
WO2006060456A2 (fr) * 2004-11-30 2006-06-08 Plexxikon, Inc. Composes actifs sur les ppar
AU2006279496A1 (en) 2005-08-17 2007-02-22 Wyeth Substituted indoles and use thereof
US20070072904A1 (en) * 2005-09-07 2007-03-29 Jack Lin PPAR active compounds
SI2046740T1 (sl) 2006-07-22 2012-12-31 Oxagen Limited Spojine s crth2 antagonistiäśno aktivnostjo
PE20090159A1 (es) * 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
KR101644170B1 (ko) 2008-01-18 2016-08-01 옥사겐 리미티드 씨알티에이치2 길항제 활성을 갖는 화합물
US8168673B2 (en) 2008-01-22 2012-05-01 Oxagen Limited Compounds having CRTH2 antagonist activity
US20100022613A1 (en) 2008-01-22 2010-01-28 Oxagen Limited Compounds Having CRTH2 Antagonist Activity
NZ720946A (en) 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2014139388A1 (fr) * 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
WO2018002673A1 (fr) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3557142A (en) 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
IE47592B1 (en) 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
US4283539A (en) 1979-12-18 1981-08-11 Pfizer Inc. Isoquinoline acetic acids
US4363912A (en) * 1980-12-15 1982-12-14 Pfizer Inc. Indole thromboxane synthetase inhibitors
US4442118A (en) * 1981-07-23 1984-04-10 Ayerst, Mckenna & Harrison, Inc. Aldose reductase inhibition by 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
DE3684410D1 (de) 1985-11-07 1992-04-23 Pfizer Heterocyclische oxophthalazinylessigsaeure.
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4960785A (en) 1988-12-16 1990-10-02 Pfizer Inc. Indolinone derivatives
WO1993012786A1 (fr) 1986-07-10 1993-07-08 Howard Harry R Jr Derives d'indolinone
US4868301A (en) 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
US5064852A (en) * 1988-12-16 1991-11-12 Pfizer Inc. Indolinone derivatives
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
GB8916774D0 (en) * 1989-07-21 1989-09-06 Bayer Ag New indole derivatives,a process for their preparation and their use in medicaments
US5304557A (en) 1989-12-15 1994-04-19 Pfizer Inc. Substituted oxoophthalazinyl acetic acids and analogs thereof
US5312829A (en) * 1990-05-21 1994-05-17 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives
US5236945A (en) 1990-06-11 1993-08-17 Pfizer Inc. 1H-indazole-3-acetic acids as aldose reductase inhibitors
US5116753A (en) * 1991-07-30 1992-05-26 The Salk Institute For Biological Studies Maintenance of pancreatic islets
GB9122590D0 (en) 1991-10-24 1991-12-04 Lilly Industries Ltd Pharmaceutical compounds
JP3195455B2 (ja) 1993-01-06 2001-08-06 ウェルファイド株式会社 キノリン−３−酢酸誘導体、その製造法と用途
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
AU7634694A (en) 1993-08-20 1995-03-21 University Of Medicine And Dentistry Of New Jersey Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same
GB9317764D0 (en) * 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
US5641800A (en) 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
TW401301B (en) * 1994-10-07 2000-08-11 Takeda Chemical Industries Ltd Antihypertriglyceridemic composition
US5700819A (en) 1994-11-29 1997-12-23 Grelan Pharmaceutical Co., Ltd. 2-substituted benzothiazole derivatives and prophylactic and therapeutic agents for the treatment of diabetic complications
IL117208A0 (en) 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
JPH09165371A (ja) 1995-10-09 1997-06-24 Sankyo Co Ltd 複素環化合物を含有する医薬
ES2224632T3 (es) * 1998-03-31 2005-03-01 The Institutes For Pharmaceutical Discovery, Inc. Acidos indolalcanoicos sustituidos.
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
WO2001064205A2 (fr) * 2000-03-02 2001-09-07 The Institutes For Pharmaceutical Discovery, Llc Compositions contenant un acide indol-alkanoique substitue et inhibiteur d'enzyme de conversion de l'angiotensine

Also Published As

Publication number Publication date
KR20010086075A (ko) 2001-09-07
YU40101A (sh) 2005-07-19
DE69916881D1 (de) 2004-06-03
US20030216452A1 (en) 2003-11-20
SK7352001A3 (en) 2002-06-04
ATE265210T1 (de) 2004-05-15
US20060074114A1 (en) 2006-04-06
WO2000032180A3 (fr) 2000-11-16
CN1368883A (zh) 2002-09-11
DE69916881T2 (de) 2005-02-03
NO20012690D0 (no) 2001-05-31
EE200100296A (et) 2003-02-17
BR9915882A (pt) 2001-08-21
ID30037A (id) 2001-11-01
AU770925B2 (en) 2004-03-11
US20100324105A1 (en) 2010-12-23
US6964980B2 (en) 2005-11-15
AP2001002146A0 (en) 2001-06-30
US6555568B1 (en) 2003-04-29
JP2002531398A (ja) 2002-09-24
IL143247A0 (en) 2002-04-21
AU2161600A (en) 2000-06-19
EP1135124B1 (fr) 2004-04-28
TW584560B (en) 2004-04-21
TNSN99224A1 (fr) 2005-11-10
HK1046372A1 (zh) 2003-01-10
HUP0104953A2 (hu) 2002-07-29
ZA200104126B (en) 2002-05-21
US20120065203A1 (en) 2012-03-15
MXPA02003118A (es) 2004-04-21
EP1135124A2 (fr) 2001-09-26
BG105531A (en) 2001-12-31
OA12035A (en) 2006-05-02
CA2385845A1 (fr) 2000-06-08
CZ20011864A3 (cs) 2002-03-13
PL349016A1 (en) 2002-06-17
HUP0104953A3 (en) 2002-08-28
WO2000032180A2 (fr) 2000-06-08
NO20012690L (no) 2001-07-27
TR200101539T2 (tr) 2001-12-21

Similar Documents

Publication Publication Date Title
DZ2953A1 (fr) Méthodes de réduction des niveaux de glucose et triglycérides en sérum et pour suppression de l'anti-genèse utilisant les acides la indoleakanoique.
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
WO1999049807A3 (fr) Procede et dispositif pour realiser une modification biologique d'un fluide
EP1107702A4 (fr) Ameliorations par ultra-sons de l'injection de medicaments
MA25530A1 (fr) Les diaminothiazoles et leur utilisaion pour inhiber les proteines-kinases.
AU2470299A (en) Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and st. john's wort for the treatment of mental disturbances
IT1292841B1 (it) Metodo e dispositivo per l'allineamento di prodotti.
MA25234A1 (fr) Vibromasseur pour le soulagement des maux et de la douleur.
IT1304008B1 (it) Dispositivo per l'eliminazione di ratti e simili.
DE69612607D1 (de) Lager mit Partikelfalle
PT1152756E (pt) Derivados de anticonvulsivo uteis no tratamento do autismo
DE69500167D1 (de) Wässrige Lösung zur Oberflächenbehandlung von Metallen
BR9609081A (pt) Combinações de substáncias ativas
FI956058A0 (fi) Menetelmä glutaaridialdehydin valmistamiseksi
ID30458A (id) Osanetan dalam pengobatan gangguan jiwa
ITTO950645A0 (it) Elettrodo per l'acquisizione di un segnale biologico di natura elettrica, in particolare un segnale elettrocardiografico.
DZ3449A1 (fr) Composition sous forme d'emulsion appropriee pour le traitement de l'hyperhidrose et/ou bromhidrose plantaire.
BR9804846A (pt) M-todo de tratamento e quadro de bicicleta contra corrosÆo e quadro de bicicleta assim obtido
AU8817098A (en) Treatment of liquid waste
AU2159300A (en) Combinations of st. john's wort and fatty acids
IT243200Y1 (it) Profilo assemblato per la costruzione di serramenti in alluminio-pvc-legno scomponibile per consentire la separata riutilizzabilita' dei
IT1291419B1 (it) Gruppo illuminante per l'illuminazione di acquari,terrari e simili.
FR2714922B1 (fr) Agencement d'éléments préfabriqués applicable au domaine de la décoration.
DE59604915D1 (de) Entschwefelungsmittel zur koinjektions-behandlung von roheisenschmelzen
IT1310187B1 (it) Sollevatore per ruote di veicoli e metodo per l'impiego dello stesso.